The Global Cell Therapy Industry Continues to Rise during the Second and Third Quarters of 2012  by Mason, Chris et al.
Cell Stem Cell
Industry ProgressThe Global Cell Therapy Industry
Continues to Rise during
the Second and Third Quarters of 2012Chris Mason,1,* Mark J. McCall,2 Emily J. Culme-Seymour,3 Shalini Suthasan,1 Simon Edwards-Parton,1
Gregory A. Bonfiglio,4,5 and Brock C. Reeve6
1The Advanced Centre for Biochemical Engineering, University College London, Torrington Place, London, WC1E 6BT, UK
2Centre for Biological Engineering, Holywell Park, Loughborough University, Loughborough, Leicestershire, LE 11 3TU, UK
3London Regenerative Medicine Network, 14a Clerkenwell Green, London, EC1R 0DP, UK
4Proteus Venture Partners, Portola Valley, CA 94028, USA
5Centre for Commercialization of Regenerative Medicine, Toronto, ON, M5G 1L5, Canada
6The Harvard Stem Cell Institute, Holyoke Centre, Massachusetts Avenue, Cambridge, MA 02138, USA
*Correspondence: chris.mason@ucl.ac.uk
http://dx.doi.org/10.1016/j.stem.2012.11.013
During Q2-Q3 2012, the cell therapy industry benefited from a number of positive external influences
including advantageous changes to future FDA regulation, but stock market activity was highly mixed. The
FDA approved two more products and an appreciable number of public-company-sponsored clinical trials
are progressing through phases 1–3.This Industry Progress update covers the
publically traded cell therapy companies
for the period April 1st to September 30th
2012, and includes key translational and
commercial activities in the form of busi-
ness news, stock market movement,
and clinical trials. After a mixed start to
the year (Brindley et al., 2012), the cell
therapy sector has overall made steady
progress during the second and third
quarters of 2012 including two FDA regu-
latory approvals for cord blood prod-
ucts—HPC (University of Colorado Cord
Blood Bank) and Ducord (Duke University
School of Medicine), bringing the total for
the year to three, with Organogenesis
gaining approval for Gintuit in March
(Schmidt, 2012).
Major External Influences
In addition to the upbeat outlook in Wash-
ington for biotechnology (Fox, 2012a),
during Q2 and Q3 there were four over-
arching events that will have a positive
effect on the sector’s commercial activi-
ties in the short and medium term.
US Legislation
In July, the US Congress passed the FDA
Safety and Innovation Act (FDASIA). This
new law includes the reauthorization of
the Prescription Drug User Fee Act
(PDUFA 5), expands the existing Acceler-
ated Approval Pathway, and creates a
‘‘breakthrough therapies’’ category for
promising new treatments for serious dis-
ease to shorten their development time-line (Fox, 2012b). All these developments
are excellent news for cell therapy com-
panies working on innovative therapies.
Increased Commercial Activity by
CIRM
The California Institute for Regenerative
Medicine (CIRM) is continuing to expand
its funding to commercial organizations
(Trounson, 2012). StemCells (Newark,
CA, USA) is one of a number of Califor-
nia-based companies to receive substan-
tial funding. In September, StemCells
received an additional $20M to help fund
Investigational New Drug (IND) enabling
activities for the deployment of human
neuronal stem cells (HuCNS-SCs) in
Alzheimer’s disease. Under the terms of
this CIRM program (RFA 10-05), funding
for companies is in the form of unsecured,
nonrecourse, interest-bearing term loans,
which will be forgivable in the event
the funded research fails to result in a
commercialized product. However, if the
product is successfully commercialized,
CIRM would earn beneficial milestone
payments depending on the degree of
success. This pragmatic funding arrange-
ment enables commercial products to be
developed while not diluting the share-
holdings of existing shareholders. Up to
the end of Q3, CIRM’s governing board
approved a total of $1.7B in funding. Cell
therapy companies that have benefited
include BioTime ($4.7M); Bluebird Bio
($9.4M); Capricor ($19.8M); Escape Ther-
apeutics ($1.5M); StemCells ($40.1M);Cell Stem Cell 11,and ViaCyte (previously Novocell; $26M).
CIRM also signed a $25M product-
backed loan agreement with the former
human embryonic stem cell-based com-
pany, Geron, in May 2011 to support their
spinal cord injury trial. Geron’s obligation
for repayment was to be contingent on
the commercial success of their embry-
onic stem cell-derived oligodendrocyte
progenitors for spinal cord injury. Geron
received $6.4M of the loan, which the
company repaid in full with accrued
interest after discontinuing their stem
cell program in November 2011.
US Defense Department Funding
The cell therapy sector continues to
attract significant US defense interest. In
September, Cytori Therapeutics (San
Diego, CA, USA) were awarded a contract
worth up to $106M by the US Department
of Health and Human Service’s Biomed-
ical Advanced Research and Develop-
ment Authority (BARDA). The funding is
for the development of Cytori’s point-of-
care processing device (Celution) of
adipose-derived stem cells for use in
thermal burns with radiation injury. The
contract is initially for 2 years but extend-
able up to 5. BARDA will support all the
preclinical, regulatory, clinical, and tech-
nology development activities needed to
satisfy the FDA’s approval process. Other
major defense deals include treatments
for acute radiation syndrome with
Osiris Therapeutics in 2008 winning a US
Department of Defense contract worthDecember 7, 2012 ª2012 Elsevier Inc. 735
Figure 1. Share Price Movement for the First Three Quarters of 2012 Compared to the Close of Q4 2011
The share price for the end of 2011 was taken as the base point, and the percentage change from this for each quarter for individual companies has been plotted.
The graph order of the companies was then established in terms of their overall change to the end of Q3 2012, with those that had the biggest Q4 2011 to Q3 2012
positive change on the left. Splits and reverse splits have been factored in. See also Table S1 for the underlying stock price information used to generate this
graph.
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cells) development and procurement,
and Cellerant in 2011 being awarded
a similar contract from BARDA worth up
to $153M to develop and stockpile CLT-
008 (myeloid progenitor cells).
UK Inquiry into Regenerative
Medicine
In July, the Science and Technology
Committee of the UK House of Lords
launched an inquiry into regenerative
medicine. Lord Krebs, Chair of the
Committee, has stated that, ‘‘.The UK
has an excellent track record of research
in this area, but we want to find out if
Government is doing enough to address
regulatory barriers and challenges to
innovation in this field. Regenerative
medicine has the potential not only to
lead to significant improvements in the
treatment of chronic diseases, such as
diabetes and certain kinds of blindness,
but also to be a driver of growth for the
pharmaceutical sector, thus contributing
to the growth of UK plc.’’ A number of736 Cell Stem Cell 11, December 7, 2012 ª2leading UK and US industrialists are
scheduled to give evidence during the
course of the inquiry, which will report
back with its recommendations to the
UK Government in the spring of 2013.
Stock Market Activity
Overall the public biotechnology sector
has seen very healthy growth during
2012, as exemplified in the NASDAQ
Biotech Index increasing by 37% during
the first three quarters of 2012 (Yang,
2012). The cell therapy companies, by
contrast, have experienced very mixed
fortunes, although fortunately not at the
level of volatility experienced by the
sector prior to 2010 (Brindley et al.,
2011). A few companies have improved
their status, including Immunocellular
Therapeutics, which became listed on
the NYSE MKT, and a few have dropped
down, for example Tengion, which moved
to the OTCQB tier of the OTC Markets
Group following an inability to regain
compliance with NASDAQ listing rules.
Prima BioMed achieved a dual listing of012 Elsevier Inc.its shares on the Australian Securities
Exchange and NASDAQ. At least one
Initial Public Offering (IPO) was post-
poned—Argos Therapeutics (Durham,
NC, USA), a dendritic-cell-based immu-
notherapy firm cofounded by Nobel Prize
winner Ralph Steinman, withdrew its
$65M float due to ‘‘market conditions.’’
Lifebank (Toronto, ON, Canada) was
taken back into private ownership by
Insception (Mississauga, ON, Canada),
a move that might herald the beginning
of a number of mergers and acquisitions
in the cord blood banking sector. The
general market trend after a challenging
start to the year shows that share prices
for the sector have been steadily improv-
ing for the majority of companies—see
Figure 1 and Table S1 available online.
Clinical Trial Activity
Clinical trial progress is a good indicator
as to the health of a particular therapeutic
sector. However, cell therapy trials are
largely sponsored by clinicians rather
Figure 2. Clinical Trial Data for Ongoing Clinical Trials being Conducted by Publicly Listed Cell Therapy Companies at the Close of Q3 2012
Data was solely sourced from http://www.clinicaltrials.gov and only includes the ‘‘ongoing’’ cell therapy trials for the individual companies (i.e., they do not include
their other non-cell-based activities) and for where the company acted as a ‘‘sponsor’’ and/or ‘‘collaborator.’’ Multinational pharma, biotech, and medical device
companies are excluded. See Table S2 for the underlying data used to generate this graph.
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et al., 2012). To gauge the industry’s over-
all activity, we have collected data on the
recruitment status at the end of Q3 2012
on clinical trials registered on http://
www.clinicaltrials.gov that were being
progressed by publicly traded cell therapy
companies (as sponsors or collaborators)
to obtain a baseline level for future
Industry Progress reports. Multinational
pharma, biotech, and medical device
companies are also undertaking a number
of cell therapy clinical trials (McKernan
et al., 2010), but we have chosen to
restrict our analysis to public companies
that focus primarily on cell therapy. In
total, 24 companies were actively listed
as currently pursuing clinical trials, with
self-reported statuses of ‘‘Not yet re-
cruiting,’’ ‘‘Recruiting,’’ ‘‘Enrolling by invi-
tation,’’ ‘‘Available,’’ or ‘‘Active, not re-
cruiting.’’ Overall, there were 67 studies
listed—61 trials in phases 1–4, 3 Observa-
tional studies, 2 Expanded Accessstudies, and 1 Compassionate use study.
Of the phase 1–3 trials (i.e., pre-FDA Bio-
logical Application License stage), 43%
were in phase 1-phase1/2, 42% were in
phase 2-phase 2/3, and 15% were in
phase 3. Overall, 48% are actively recruit-
ing, 37% are active but not recruiting (i.e.,
patients are being treated or examined),
and 13% are waiting to start enrolment.
The individual company data are aggre-
gated in Figure 2 with the underlying raw
data in Table S2.
Company News
Advanced Cell Technology (ACT) (Marl-
borough, MA, USA) enrolled the final
patient in the first cohort for their European
phase 1/2 clinical trial for Stargardt’s
macular dystrophy using retinal pigment
epithelial cells derived from human em-
bryonic stem cells. Together with a similar
trial in the USA, started in July 2011, the
total number of Stargardt’s patients
treated by ACT as of July 2012 was ten.Cell Stem Cell 11,Athersys (Cleveland, OH, USA)
completed enrolment of the first cohort
of their phase 2 double blind, placebo-
controlled trial of adult stem cells
(MultiStem) for moderate to severe stroke
patients. Cells or placebo were adminis-
tered 24–36 hr after the initial ischemic
event. An independent safety committee
reviewed the data and recommended
proceeding with higher cell doses for the
remainder of the phase 2 trial.
BioSante (Lincolnshire, IL, USA) are
continuing to recruit the 15 subjects for
their phase 2 open label study of myeloma
patients with near complete remission.
The approach is a combination therapy
consisting of BioSante’s GVAX myeloma
vaccine together with lenalidomide (Revli-
mid, Celgene). GVAX cells are genetically
modified to secrete granulocyte macro-
phage colony stimulating factor (GM-
CSF) and then irradiated to prevent further
cell division while retaining metabolic
activity.December 7, 2012 ª2012 Elsevier Inc. 737
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wholly owned subsidiary, BioTime Acqui-
sition Corporation, to acquire businesses
and assets in the areas of stem cell and
regenerative medicine. The former Presi-
dent andChief Executive Officer of Geron,
Tom Okarma, will serve as its Chief Exec-
utive Officer. Since 2010, BioTime has
made a number of strategic acquisitions
including purchasing ES Cell Interna-
tional, a Singapore company responsible
for producing the first human embryonic
stem cells generated under good man-
ufacturing practice (GMP) conditions.
BrainStorm Cell Therapeutics (Petach
Tikva, Israel) has submitted a report
to the Israeli Ministry of Health on the
planned interim safety review of the use
of NurOwn cells (autologous mesen-
chymal stem cells differentiated into
specialized, neuron-supporting cells) in
a phase 1/2 amyotrophic lateral sclerosis
(ALS) clinical trial. Brainstorm plans to
move their ALS program forward with
expanded studies involving the University
of Massachusetts Medical School and
Massachusetts General Hospital (Boston,
USA). NurOwn has already been granted
orphan-drug designation by the FDA.
Dendreon (Seattle, WA, USA) in July
announced a major restructuring pro-
gram. The plan includes the closure of
one of its three manufacturing facilities
(Morris Plains, NJ factory), and restruc-
turing administrative functions, includ-
ing a reduction over the coming year in
headcount of more than 600 full-time
staff and contractors. The projected
savings are in the order of $150M p.a.
More importantly, the restructuring is
expected to dramatically reduce the
cost of goods for producing Provenge
(sipuleucel-T; approved by the FDA
in 2010 for asymptomatic or minimally
symptomatic metastatic castrate-resis-
tant prostate cancer).
Fibrocell (Exton, PA, USA) published
the data from the pivotal clinical trial of
their bioaesthetic cell product, LaViv
(azficel-T), for the improvement of the
appearance of moderate/severe nasola-
bial fold wrinkles, better known as ‘‘facial
smile lines.’’ Overall, the data demon-
strated statistically significant improve-
ment in appearance of smile line wrinkles.
LaViv received regulatory approval from
the FDA in June 2011 and remains the first
bioaesthetic cell therapy to gain such
approval.738 Cell Stem Cell 11, December 7, 2012 ª2Human Stem Cells Institute (Moscow,
Russia) is Russia’s first public bio-
technology company. The main focus
is R&D, the commercialization and
marketing of cell- and gene-based tech-
nologies, and cord blood banking,
through the ownership of Gemabank, the
largest private cord blood bank in Russia.
In May 2012, the company received
marketing authorization from the Federal
Service for Supervision of Healthcare
and Social Development of the Russian
Federation for the Celution 800 System.
The device is manufactured by Cytori.
ImmunoCellular Therapeutics (Los
Angeles, CA, USA) rang the Opening
Bell at the New York Stock Exchange
(NYSE) on July 19th 2012 to mark, in the
traditional manner, the company’s inclu-
sion in the NYSE MKT. The firm’s shares
had begun trading on the NYSE in late
May 2012.
Lifebank (Toronto, Canada) was wholly
acquired in late September and taken
back into the private sector by Insception
Biosciences (Mississauga, Canada), the
largest cord blood banking company in
Canada. Insception paid CAN $0.495 in
cash per share valuing Lifebank at CAN
$5.6M—1.75 times their annual revenue
of CAN $3.2M for both 2010/11 and
2011/12. It is interesting to compare this
deal to the only other recent cash acquisi-
tion of a revenue-generating cell therapy
company, i.e., the $750M that Shire paid
for Advanced BioHealing in May 2011.
This particular acquisition gave a revenue
multiplier of 5.1 (ABH $147M annual
revenue in 2010 up from $8.6M in 2007).
Medipost (Seoul, Korea) announced
in June the commencement of clinical
deployment of its first commercial cell
therapy product: Cartistem. Cartistem
was approved by the Korean Food and
Drug Administration (KFDA) in 2011. Car-
tistem is an allogeneic cell-based therapy
for the treatment of cartilage defects,
such as those present in osteoarthritis.
The therapy is produced under GMP con-
ditions using human umbilical cord blood-
derived mesenchymal stem cells mixed
with a viscous biocompatible polymer.
Medistem (San Diego, CA, USA) have
gained a significant investor and advisor
in Gene Ray, who is a Ph.D. in theoretical
physics, inventor, and entrepreneur. He
was the founder of the Titan Corporation
(San Diego), a major provider of commu-
nications equipment and services to the012 Elsevier Inc.US government, which he sold for $2.6B
in 2005 to L-3 Communications.
Neuralstem (Rockville, MD, USA) has
granted a license for use of its Spinal
Cord Delivery Platform and Floating
Cannula to Q Therapeutics (Salt Lake
City, UT, USA). This platform and cannula
were deployed in Neuralstem’s phase 1
ALS trial for implanting NSI-566 neural
stem cells into the spinal cords of 18
ALS patients. The trial was to assess
both the safety of NSI-566s and the
intraspinal transplantation method. Q
Therapeutics, which was cofounded by
Mahendra Rao (now Director of the NIH
Center for Regenerative Medicine), is
likewise targeting ALS with their Q-Cell
product (glial progenitors). The licensing
and use of common platform technolo-
gies by multiple companies will help
facilitate much-needed standardization
in the sector.
Northwest Biotherapeutics (Bethesda,
MD, USA) received permission from the
FDA to evolve its phase 2 clinical trial
of DCVax-L (autologous dendritic cells
pulsed with tumor lysate antigen) for glio-
blastomamultiforme (GBM) into a phase 3
study. The original phase 2 studywas initi-
ated in 2006 to determine the safety and
efficacy of DCVax-L in approximately 90
patients with GBM after their tumors
were treated with a combination of sur-
gery and radiotherapy. The FDA accepted
amendment enables the initial trial to
become a phase 3 trial to evaluate the
impact on disease progression and
survival time, as well as safety, in up to
300 patients.
Opexa (The Woodlands, TX, USA) has
rebranded its multiple sclerosis (MS)
candidate cell therapy with a new name:
Tcelna. Previously known as Tovaxin,
Tcelna (pronounced Te-SELL-nuh) re-
flects its source: T cells isolated from
peripheral blood and expanded in culture,
prior to subcutaneous implantation, with
the aim of potentially reducing the risk
of MS.
Osiris Therapeutics’ (Columbia, MD,
USA) lead product, Prochymal (intrave-
nous formulation of mesenchymal stem
cells), received approval in Canada and
New Zealand for the treatment of acute
graft-versus-host disease (GvHD) in
children. Prochymal is now available in a
total of nine countries including the USA,
under an FDA Expanded Access Pro-
gram. In September, Osiris announced
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collaboration with Genzyme (purchased
by Sanofi for $20B in 2011). All rights
to Prochymal and Chondrogen (intra-
articular injection of human mesenchymal
stem cells) worldwide have reverted back
to Osiris.
Pluristem (Haifa, Israel) are nearing
completion of their new 28,000 square
foot GMP production facility. In July
2011, Pluristem contracted with MTM
(Haifa) for the leasing and construction of
a state-of-the-art manufacturing facility
in order to bioprocess PLX (mesen-
chymal-like adherent stromal cells
derived from full term placenta) cell pro-
duct candidates for a variety of medical
indications. The facility’s design is aimed
to specifically meet Israeli Ministry of
Health, FDA, and EMA regulations.
ReNeuron (Guildford, Surrey, UK)
received independent Data Safety Moni-
toring Board (DSMB) clearance to prog-
ress to the higher dose in their open label
phase 1 safety study of ReN001 in stable
ischemic stroke patients.
Sernova (London, Ontario, Canada) has
received Health Canada approval to
conduct a clinical trial to assess the safety
and efficacy of their Cell Pouch platform
technology with transplanted pancreatic
islets in diabetic patients, in collabora-
tion with Principle Investigator, James
Shapiro, at the University of Alberta
Health Science Centre in Edmonton.
James Shapiro was one of the pioneers
of the now highly successful Edmonton
Protocol that revolutionized islet cell
transplantation in the 2000s.
TiGenix (Leuven, Belgium) have re-
ceived EMA approval of their new Euro-
pean production facility in Sittard Geleen
(Netherlands) for the bioprocessing of
ChondroCelect (autologous chondro-
cytes for knee cartilage repair).
Tengion (Winston-Salem, NC, USA)
havemade significant progress in improv-
ing their near bankrupt financial status.
In September 2012, Tengion obtained
a 1 month $1M bridging loan to tide
them over until more substantial funding
could be put in place. This in turn was
achieved on October 10th, with the
closing of a private investment of $15M
of Senior Secured Convertible Notes.The investors included Celgene, RA
Capital Management, Deerfield Manage-
ment, Bay City Capital, and HealthCap.
As part of its investment, Celgene
secured a right of first negotiation on the
Tengion’s Neo-Urinary Conduit program.
Vita 34 (Leipzig, Germany), the oldest
private cord blood bank in the German-
speaking countries, has taken over
BioPlanta (Leipzig). BioPlanta is a biotech-
nology firm that produces plant-active
compounds and fine chemicals for
the environmental and pharmaceutical
sectors. Since 2011, Vita 34 has been
collaborating with BioPlanta to develop
a method to produce antifreeze proteins
in plants for the cryopreservation of stem
cells.
Summary
During the periods Q2 and Q3 2012, cell
therapy has continued to demonstrate
its unique approach to 21st century
healthcare and will benefit from a number
of recent and highly favorable external
influences, including the upbeat mood in
Washington for biotechnology and poten-
tially advantageous changes to future
FDA regulation. There have been two
further FDA CBER regulatory product
approvals, bringing the total number to
seven. Overall the industry has had highly
mixed stock market activity. There
are now a sizeable number of public-
company-sponsored clinical trials across
phases 1–3. With approximately 50
publically traded companies with a
combined market capitalization of over
$7B and growing annual revenues cur-
rently in excess of $1B spread across
Asia, Europe, and North America, the
industry’s position as a sector in its own
right is no longer in any doubt.
SUPPLEMENTAL INFORMATION
Supplemental Information for this article includes
Tables S1 and S2 (data and their sources) and
can be found with this article online at http://dx.
doi.org/10.1016/j.stem.2012.11.013.
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